Edwards Lifesciences (EW) Stock
Heart valve and critical care monitoring leader. Here's the price, business snapshot, and what's worth knowing about Edwards Lifesciences in July 2026.
Edwards Lifesciences Corporation (EW) is a medical-technology company focused on heart valves and critical-care monitoring. It is best known for the Sapien transcatheter aortic valve replacement (TAVR) system and a broad range of surgical valves and haemodynamic monitoring products. Investors typically monitor Edwards for its leadership in structural heart therapies, clinical-driven innovation, and exposure to an ageing population that boosts demand for valve procedures. Revenue growth is linked to procedure volumes, reimbursement environments and the success of clinical trials and new indications. The company invests in R&D and selective acquisitions to extend its portfolio and geographic reach. Key risks include competition, regulatory and reimbursement shifts, and sensitivity to elective-procedure cycles. This is general educational information only and not personalised financial advice; values can rise or fall and past performance is not a reliable guide. Consider your own circumstances or consult a financial adviser before making investment decisions.
Why It’s Moving
EW stays in focus as analysts keep a constructive tone, but the near-term upside case looks measured.
- Analyst sentiment remains constructive, with multiple recent consensus checks still showing EW in the Buy to moderate buy range, suggesting Wall Street expects the stock to keep grinding higher rather than re-rate sharply.
- The latest forecast snapshots show a fairly tight target band versus the current share price, which can temper enthusiasm and signal that investors are waiting for a clearer catalyst before pushing the stock much further.
- With no major company-specific event in the past week provided here, the stock’s move is likely being shaped more by broader healthcare and medtech positioning than by a fresh headline from Edwards Lifesciences.
EW stays in focus as analysts keep a constructive tone, but the near-term upside case looks measured.
- Analyst sentiment remains constructive, with multiple recent consensus checks still showing EW in the Buy to moderate buy range, suggesting Wall Street expects the stock to keep grinding higher rather than re-rate sharply.
- The latest forecast snapshots show a fairly tight target band versus the current share price, which can temper enthusiasm and signal that investors are waiting for a clearer catalyst before pushing the stock much further.
- With no major company-specific event in the past week provided here, the stock’s move is likely being shaped more by broader healthcare and medtech positioning than by a fresh headline from Edwards Lifesciences.
When is the next earnings date for EDWARDS LIFESCIENCES CORP (EW)?
Edwards Lifesciences (EW) is scheduled to report its next earnings on July 23, 2026, covering the second quarter of 2026 . The company's earnings call is set for 5:00 PM ET, where executives will discuss financial results and outlook for Q2 2026 . This date aligns with the company’s historical reporting pattern, as the previous Q1 2026 report was released on April 23, 2026 . Analysts estimate an EPS of $0.74 and quarterly revenue of $1.70B for this upcoming report .
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Edwards Lifesciences stock with a target price of $95.77, indicating potential growth.
Financial Health
Edwards Lifesciences is performing well with strong profits and cash flow, supporting its growth potential.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
Abbott
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
AGILENT TECHNOLOGIES INC
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.
ALIGN TECHNOLOGY INC
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
Baskets Featuring EW
Boston Scientific Penumbra Deal (Cardiovascular M&A)
Boston Scientific is set to acquire Penumbra for $14.5 billion, marking a significant expansion into the high-growth thrombectomy and neurovascular device markets. This major consolidation could catalyze further M&A activity, creating investment opportunities among other innovative companies in the cardiovascular sector.
Published: 17 January 2026
Explore BasketMedTech Stocks: Brazil Market Risks & Opportunities
Brazil's growing demand for advanced healthcare presents an opportunity to modernize its medical infrastructure and improve patient outcomes. This basket offers exposure to the leading US and European companies supplying Brazil with robotic surgery systems, AI diagnostics, and innovative medical devices.
Published: 21 October 2025
Explore BasketWearable Tech IP Wars: What Investors Should Know
Masimo's lawsuit against U.S. Customs, following a reversal of an import ban on Apple Watches, highlights the fierce competition over intellectual property in wearable health. This theme focuses on the medical technology companies and competitors poised to benefit from the ongoing patent battles in the lucrative health-monitoring device market.
Published: 21 August 2025
Explore BasketWhy You’ll Want to Watch This Stock
Leader in TAVR
Edwards holds a strong position in transcatheter aortic valve replacement; adoption and expanded indications can support growth, though procedure volumes can fluctuate.
Clinical-driven innovation
Ongoing trials and new device launches are central to long-term prospects, but regulatory outcomes and trial timing can influence performance.
Demographics & reach
An ageing global population and geographic expansion present opportunities, while reimbursement and local regulation remain important considerations.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
